Presented By: Adolfo Garcia-Sastre, PhD
Speaker Biography: Dr. García-Sastre is Professor in the Departments of Microbiology and Medicine and in the Tisch Cancer Center at Icahn School of Medicine Mount Sinai (ISMMS) in New York,. He is also Director of the Global Health and Emerging Pathogens Institute at ISMMS, and Principal Investigator for the Center for Research on Influenza Pathogenesis (CRIP), one of five NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS). For the past 30 years, his research interest has been focused on the molecular biology, virus-host interactions, innate immunity and pathogenesis of influenza viruses and several other RNA viruses, as well as on the development of new vaccines and antivirals. He has more than 500 peer-reviewed publications in these areas of research. He has been President of the International Society for Vaccines in 2014-2015. He is Editor for the scientific journals PLoS Pathogens, Journal of Virology and Virus Research. In 2017, he has been elected a fellow of the Royal Academy of Pharmacy in Spain. In 2019, he was recognized with a Honorary Doctor Degree from the University of Burgos, Spain. Also in 2019, he was elected a member of the National Academy of Sciences.
Webinar: Keynote Presentation: A Newcastle Disease Virus-Based COVID-19 Vaccine with Live Q&A
Webinar Abstract: Vaccines against SARS-CoV-2 have been made in a record time. However, although the vaccines that have been deployed have clearly reduced the percentage of severe infections in countries where they have been widely used, many developing countries have problems to afford the purchase and/or distribution of approved vaccines. In addition, current vaccines provide with limited mucosal immunity to appropriately prevent infections. New efficacious and safe SARS-CoV-2 vaccines that could be manufactured locally in developing countries, that would not require ultra-congelation and that would induce infection-preventing mucosal immunity are desirable. We have been working in the development of such a vaccine based on a Newcastle disease virus (NDV) vector. This avian virus is widely used as live and inactivated vaccine in poultry against Newcastle disease, a potentially devastating avian disease. NDV inoculation in mammals results in abortive infection due to the induction of a robust local innate immune response that inhibits further virus replication while potentiating the induction of adaptive immune responses. NDV vaccines are manufactured using the same technology as most of the influenza virus vaccines, making it possible its production in most developing countries. We have generated NDV-based vaccines expressing a stabilized version of the S protein of SARS-CoV-2. These vaccines are stable at 2 degrees and provide protection against SARS-CoV-2 and its variants in animal models.
Earn PACE Credits:
1. Make sure you’re a registered member of Labroots ([ Ссылка ])
2. Watch the webinar on YouTube or on the Labroots Website ([ Ссылка ])
3. Click Here to get your PACE credits (Expiration date – October 19, 2024): ([ Ссылка ])
Labroots on Social:
Facebook: [ Ссылка ]
Twitter: [ Ссылка ]
LinkedIn: [ Ссылка ]
Instagram: [ Ссылка ]
Pinterest: [ Ссылка ]
SnapChat: labroots_inc
